Antibody Dynamics in Japanese Paediatric Patients with Influenza A Infection Treated with Neuraminidase Inhibitors in a Randomised Trial

Overview

Journal Sci Rep

Specialty Science

Date 2019 Aug 17

PMID 31417163

Citations 2

Authors

Nobuo Hirotsu

Yutaka Saisho

Takahiro Hasegawa

Mitsutaka Kitano

Takao Shishido

Affiliations

Soon will be listed here.

Abstract

Neuraminidase inhibitors (NAIs) complement influenza virus infection management by helping to clear virus, alleviate symptoms, and reduce transmission. In a previous randomised study, we examined the effect of 4 NAIs on virus clearance and influenza symptoms in Japanese paediatric patients. In this second analysis, we examined the effects of NAI treatment on antibody responses and virus clearance, and the relationships between antibody responses and patients' infection histories (previous infection; asymptomatic infection via household members of same virus type/subtype; vaccination), and between infection histories and viral kinetics. Haemagglutination inhibition (HI) antibody responses produced HI titres ≥40 by Day 14 of NAI treatment, in parallel with virus clearance (trend test P = 0.001). Comparing patients with and without influenza infection histories (directly or asymptomatic infection via household members) showed that infection history had a marked positive effect on HI antibody responses in patients vaccinated before the current influenza season (before enrolment). Current virus clearance was significantly faster in patients previously infected with the same virus type/subtype than in those not previously infected, and clearance pattern depended on the NAI. Assessment of anti-influenza effects of antiviral drugs and vaccines should consider virus and antibody dynamics in response to vaccination and natural infection histories.

Citing Articles

Improvement of respiratory symptoms and health-related quality of life with peramivir in influenza patients with chronic respiratory disease: Additional outcomes of a randomized, open-label study.

Kato M, Saisho Y, Tanaka H, Bando T Influenza Other Respir Viruses. 2021; 15(5):651-660.

PMID: 33683019 PMC: 8404055. DOI: 10.1111/irv.12835.

Effect of peramivir on respiratory symptom improvement in patients with influenza virus infection and pre-existing chronic respiratory disease: Findings of a randomized, open-label study.

Kato M, Saisho Y, Tanaka H, Bando T Influenza Other Respir Viruses. 2020; 15(1):132-141.

PMID: 32677375 PMC: 7767948. DOI: 10.1111/irv.12788.

References

Ng S, Fang V, Ip D, Chan K, Leung G, Peiris J . Estimation of the association between antibody titers and protection against confirmed influenza virus infection in children. J Infect Dis. 2013; 208(8):1320-4. PMC: 3778972. DOI: 10.1093/infdis/jit372. View

Ishizuka H, Toyama K, Yoshiba S, Okabe H, Furuie H . Intrapulmonary distribution and pharmacokinetics of laninamivir, a neuraminidase inhibitor, after a single inhaled administration of its prodrug, laninamivir octanoate, in healthy volunteers. Antimicrob Agents Chemother. 2012; 56(7):3873-8. PMC: 3393442. DOI: 10.1128/AAC.06456-11. View

Hirotsu N, Saisho Y, Hasegawa T, Shishido T . Clinical and virologic effects of four neuraminidase inhibitors in influenza A virus-infected children (aged 4-12 years): an open-label, randomized study in Japan. Expert Rev Anti Infect Ther. 2017; 16(2):173-182. DOI: 10.1080/14787210.2018.1421945. View

Hirotsu N, Saisho Y, Hasegawa T . The effect of neuraminidase inhibitors on household transmission in Japanese patients with influenza A and B infection: A prospective, observational study. Influenza Other Respir Viruses. 2018; 13(2):123-132. PMC: 6379638. DOI: 10.1111/irv.12590. View

Saisho Y, Ishibashi T, Fukuyama H, Fukase H, Shimada J . Pharmacokinetics and safety of intravenous peramivir, neuraminidase inhibitor of influenza virus, in healthy Japanese subjects. Antivir Ther. 2016; 22(4):313-323. DOI: 10.3851/IMP3104. View

Sato M, Hashimoto K, Kawasaki Y, Hosoya M . Immune response after a single intravenous peramivir administration in children with influenza. Antivir Ther. 2018; 23(5):435-441. DOI: 10.3851/IMP3222. View

Kohno S, Yen M, Cheong H, Hirotsu N, Ishida T, Kadota J . Phase III randomized, double-blind study comparing single-dose intravenous peramivir with oral oseltamivir in patients with seasonal influenza virus infection. Antimicrob Agents Chemother. 2011; 55(11):5267-76. PMC: 3195028. DOI: 10.1128/AAC.00360-11. View

Fonville J, Wilks S, James S, Fox A, Ventresca M, Aban M . Antibody landscapes after influenza virus infection or vaccination. Science. 2014; 346(6212):996-1000. PMC: 4246172. DOI: 10.1126/science.1256427. View

Skowronski D, Chambers C, De Serres G, Sabaiduc S, Winter A, Dickinson J . Serial Vaccination and the Antigenic Distance Hypothesis: Effects on Influenza Vaccine Effectiveness During A(H3N2) Epidemics in Canada, 2010-2011 to 2014-2015. J Infect Dis. 2017; 215(7):1059-1099. PMC: 5853783. DOI: 10.1093/infdis/jix074. View

10.

Hadjichrysanthou C, Cauet E, Lawrence E, Vegvari C, de Wolf F, Anderson R . Understanding the within-host dynamics of influenza A virus: from theory to clinical implications. J R Soc Interface. 2016; 13(119). PMC: 4938090. DOI: 10.1098/rsif.2016.0289. View

11.

Sruamsiri R, Ferchichi S, Jamotte A, Toumi M, Kubo H, Mahlich J . Impact of patient characteristics and treatment procedures on hospitalization cost and length of stay in Japanese patients with influenza: A structural equation modelling approach. Influenza Other Respir Viruses. 2017; 11(6):543-555. PMC: 5705683. DOI: 10.1111/irv.12505. View

12.

. Recommendations for Prevention and Control of Influenza in Children, 2017 - 2018. Pediatrics. 2017; 140(4). DOI: 10.1542/peds.2017-2550. View

13.

Takahashi Y, Kelsoe G . Role of germinal centers for the induction of broadly-reactive memory B cells. Curr Opin Immunol. 2017; 45:119-125. PMC: 5449227. DOI: 10.1016/j.coi.2017.03.002. View

14.

Webster A, Boyce M, Edmundson S, Miller I . Coadministration of orally inhaled zanamivir with inactivated trivalent influenza vaccine does not adversely affect the production of antihaemagglutinin antibodies in the serum of healthy volunteers. Clin Pharmacokinet. 1999; 36 Suppl 1:51-8. DOI: 10.2165/00003088-199936001-00006. View

15.

Zaraket H, Saito R . Japanese Surveillance Systems and Treatment for Influenza. Curr Treat Options Infect Dis. 2016; 8(4):311-328. PMC: 5155020. DOI: 10.1007/s40506-016-0085-5. View

16.

Camilloni B, Basileo M, Valente S, Nunzi E, Iorio A . Immunogenicity of intramuscular MF59-adjuvanted and intradermal administered influenza enhanced vaccines in subjects aged over 60: A literature review. Hum Vaccin Immunother. 2015; 11(3):553-63. PMC: 4514405. DOI: 10.1080/21645515.2015.1011562. View

17.

Clark A, DeDiego M, Anderson C, Wang J, Yang H, Nogales A . Antigenicity of the 2015-2016 seasonal H1N1 human influenza virus HA and NA proteins. PLoS One. 2017; 12(11):e0188267. PMC: 5690631. DOI: 10.1371/journal.pone.0188267. View

18.

Lv J, Hua Y, Wang D, Liu A, An J, Li A . Kinetics of pulmonary immune cells, antibody responses and their correlations with the viral clearance of influenza A fatal infection in mice. Virol J. 2014; 11:57. PMC: 3986938. DOI: 10.1186/1743-422X-11-57. View

19.

Koopman G, Mooij P, Dekking L, Mortier D, Nieuwenhuis I, van Heteren M . Correlation between Virus Replication and Antibody Responses in Macaques following Infection with Pandemic Influenza A Virus. J Virol. 2015; 90(2):1023-33. PMC: 4702706. DOI: 10.1128/JVI.02757-15. View

20.

Cao P, McCaw J . The Mechanisms for Within-Host Influenza Virus Control Affect Model-Based Assessment and Prediction of Antiviral Treatment. Viruses. 2017; 9(8). PMC: 5580454. DOI: 10.3390/v9080197. View